FOOD TRACEABILITYLEDGER

Follow the food. Preserve the record.

Standards & Interoperability · Guidance clarification

FDA's FAQ separates EPCIS interoperability from the rule's required outcome

EPCIS can be a powerful exchange option, but FDA says it is not required for compliance or for submitting traceability data to the agency.

Editorial figure by Food Traceability Ledger. Source context: U.S. Food and Drug Administration.

A standard can solve one class of exchange problem

EPCIS gives trading partners a common event model and vocabulary, which can reduce the number of custom translations needed to describe what happened, when, where, to which object, and in what business context. That value is distinct from the legal question of which KDEs a covered person must maintain or provide for a particular CTE.

A provider that supports EPCIS should be able to identify the implemented version, event types, identifiers, vocabularies, master-data dependencies, capture interfaces, query interfaces, validation, correction behavior, access controls, and partner tests. A standards logo or a statement that events are EPCIS compatible does not show which food-rule workflows are complete.

Multiple exchange paths can coexist

Many supply chains will use EDI, APIs, portals, spreadsheets, bills of lading, invoices, or other records alongside EPCIS. The operating challenge is to prevent those paths from creating conflicting versions of a shipment, receipt, lot, or location. Buyers should test how the system decides which value is authoritative and how a rejected or corrected record propagates.

Authority response is another separate path. The FDA FAQ's clarification means buyers should verify that a system can produce the required output and supporting records even if EPCIS is the partner exchange format. Export, query, and visualization features should not obscure who approved the response or what source data were excluded.

Enterprise buyer test

Translate this change into the exact population, record type, workflow stage, decision owner, effective date, and evidence that could be affected. Ask current or prospective providers to demonstrate the named workflow with representative data and an exception—not a polished feature tour. Record what official documentation establishes, what a provider states, what the team observes, and what remains unresolved.

A defensible review also identifies the dependency outside the product. Authority interpretation, policy configuration, data quality, integrations, human judgment, approval rights, release governance, training, and retained evidence may remain customer or service responsibilities. The evaluation should preserve those boundaries instead of treating a technology claim as the complete operating model.

What we will watch next

Food Traceability Ledger will watch the named source and affected market records for later evidence that changes status, scope, availability, implementation timing, workflow consequence, or the limits of the initial report. A later announcement does not silently overwrite this dated account; the change ledger preserves the sequence.

Primary source: U.S. Food and Drug Administration · Official FAQ.

Evidence boundary: This article analyzes an FDA FAQ and does not assess EPCIS conformance or compliance for any provider or business.

Editorial record: Published July 19, 2026; updated July 19, 2026. Corrections policy.

Related organizations

Explore all